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Disease of the proximal left anterior descending artery (LAD) is a common pathological finding often combined with disease in other coronary arteries. In this article we review specifically the evidence (and the guidelines arsing from the data) for lesions isolated to the proximal LAD only.
Methods
The primary aim was to perform a systematic review of the published data comparing coronary artery bypass grafting (CABG) versus percutaneous coronary intervention (PCI) for isolated stenoses of the proximal LAD. Using Medline and Google Scholar the search was limited to studies published in English between 1998 and 2014. Search keywords included ("Minimally invasive direct coronary artery bypass" OR "MIDCAB" OR 'Coronary Artery Bypass') AND ('Percutaneous Coronary Intervention' OR PCI OR primary stenting OR stenting) AND (Left Anterior Descending). To broaden the search we also crosschecked the references of the articles identified in the initial Medline results as well the references of the several published meta-analyses. Finally the references of the major guidelines discussed were also searched. Eleven studies were identified that compared baremetal stent PCI or balloon angioplasty (PCI-BMS) versus CABG and 9 studies that compared drug-eluting stent PCI (PCI-DES) versus CABG. Several observational studies were identified that compared mixed BMS and DES use against CABG and these were excluded.
Bare Metal Stents vs. CABG
Underpinning both the European guidelines and the US guidelines for revascularisation of the isolated proximal LAD stenoses are two large metaanalyses examining the outcomes of a series of historical trials comparing CABG vs. PCI (almost exclusively with BMS) for isolated proximal LAD disease: 1) Aziz et al who performed a meta-analysis of minimally invasive internal thoracic artery bypass versus percutaneous revascularisation for isolated lesions of the LAD in >1900 patients; 2) Kapoor et al who examined outcomes of isolated disease of the proximal LAD comparing the effectiveness of percutaneous coronary interventions and CABG surgery in >1200 patients. [1] [2] [3] [4] [5] Although there were no differences in either meta-analysis for mortality, myocardial infarction (MI) or stroke between the two revascularisation strategies there was a three to five fold increase in repeat target vessel revascularisation (TVR) in patients treated with PCI compared to CABG.
Although at first glance this evidence appears impressive (21 studies reporting outcomes of 3,162 patients) it is important to note is that the two meta-analyses largely reproduce the same studies and duplicate the patient numbers. After exclusion of duplicated studies the 2 meta-analyses report the findings of 11 studies of 2380 patients. The 11 studies reported in total are summarised in Table 1 . [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Additionally the two largest studies were non-randomised observational studies that may duplicate the same group of patients. 11, 13 Given the limitations of such observational data in these 2 studies the meta-analyses authors actually excluded them from their main analysis. Also it is important to note however that the largest of randomised study of PCI-BMS vs. CABG included only 220 patients.
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Therefore the meta-analyses finally report 9 studies report the outcomes of 1239 patients randomised to PCI or CABG providing the best quality data with selection and treatment biases are minimised as far a possible. between the two treatments. 8, 14 However there was a significant improvement in quality of life with both treatments at follow-up compared to baseline and such outcome data is very relevant when informing patient choice prior to treatment.
The SIMA trial recently reported the 10 year follow up of the original cohort reported in 1998 (and included in the meta-analyses). 7, 36 In this report a decade on, not one patient with a LIMA to the LAD had undergone repeat Whilst the data supporting the conclusion that PCI-BMS increase the risk of TVR three to five-fold compared to CABG appears robust, it is important to note that these remaining studies do not show any evidence of a mortality benefit with CABG vs. PCI-BMS with the benefit of CABG being exclusively driven by TLR. Two other meta-analyses of the same trials have largely reproduced the findings of the two meta-analyses reported in the 2010 guidelines. 17, 18 What does appear clear however from later large scale randomised control trials and subsequent meta-analyses is that drug-eluting stents offer a significant reduction in TLR when compared to bare metal stents. Indeed several meta-analyses of RCTs comparing first generation DES with BMS report similar rates of death, cardiac death, and non-fatal myocardial infarction, but a 50-70% relative risk reduction in repeat target vessel revascularization with DES. 19 7
Drug-eluting stents vs. CABG
In an attempt to derive further insights into comparisons between PCI-DES and CABG (and thus to draw conclusions regarding contemporary practice) we identified 9 studies of 2752 patients comparing PCI-DES with CABG for isolated LAD stenosis and these are listed in Table 2 . [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] However as with the PCI-BMS vs. CABG data the majority of the studies are observational and retrospective in design. Only 2 studies were randomised with a total of 184 patients treated by PCI-DES and 135 by CABG. 20, 24 Therefore there are very limited data from which conclusions can to drawn as to the optimal revascularisation strategy for isolated proximal LAD disease in contemporary practice. Additionally the findings from the two studies rather than being consistent are divergent. Hong et al found no difference in TLR between the PCI-DES and CABG cohorts but the very short follow-up (6-months) is a limitation and reduces the robustness of the conclusion that the two strategies offered comparable TLR rates. 20 In contrast at 12-months
Thiele et al reported a 6.2% TLR rate in the PCI-DES group vs. 0% in the CABG group, a finding which indicated a failure of a non-inferiority comparison between PCI-DES and CABG. 24 At 7-year follow-up the authors reported similar death and MI rates between the two revascularisation strategies but a very significant excess of TLR in the PCI-DES cohort (20.0% vs. 1.5%) that was highly statistically significant. 25 Although only a single study has reported on the quality of life with PCI-DES vs. CABG, as with studies comparing PCI-BMS with CABG there appears to be little difference in quality of life between treatments as measured by SF-36 at either 12-months or 7-years follow-up. 24, 25 In examining the results of the retrospective observational analyses of PCI-DES vs. CABG it is also unexpected to observe that the results favour CABG (Table 2 ).
In the absence of definitive data many interventionalists in practice are likely to undertake PCI in "straightforward" lesions and refer complex unsuitable lesions 8 for CABG. Therefore one might expect that PCI would perform well in these circumstances vs. CABG but the data as it is do not support this hypothesis. The confounding effect of baseline factors such as age and comorbidity is uncertain
and as yet unstudied. The optimal strategy in contemporary practice needs to be properly tested in an appropriately powered randomized trial to be definitive and powered to allow age and comorbidity to be sufficiently stratified.
Two meta-analyses including the randomised and observational studies for DES-PCI vs. CABG have been performed. 30, 31 In the first a subgroup analysis concluding that the PCI-DES cohort (4 studies; 456 patients) had a higher risk of recurrent angina (risk ratio 3.4, 95% CI: 1.9 to 6.2; p < 0.001) and target vessel re-interventions (risk ratio 4.16, 95% CI: 2.7 to 6.6; p < 0.001) at midterm follow-up (2-5 years). 30 The second meta-analysis considered only the randomised trials of PCI-DES vs. CABG for proximal LAD disease as part of a larger meta-analysis of stents vs. CABG but reported that the data was insufficient for any firm conclusions to be made. 31 Aside from the relative lack of data (randomised or not) and the divergent results it must be recognized that 2010 using a United States registry. 34 Mortality, MI and stroke were similar at 3-year follow-up between DES and CABG but despite the apparent contemporary practice repeat revascularisation rates were almost twice as high with DES (12.98 vs. 7.09%). Therefore even the most contemporary data (albeit registry-derived) appears to support CABG as the optimal revascularisation strategy for isolated proximal LAD disease.
The premise that proximal LAD lesions place patients at particular risk and thus deserves particular focus derives from the large territory of myocardium subtended, and hence at risk from vessel restenosis/occlusion. The left main stem subtends an even greater territory, so the recently published 5-year data from the SYNTAX trial on this sub-group is of some reassurance to interventionalists in the current proximal LAD data void. 35 Although it is tempting to extrapolate the SYNTAX left main data to support a PCI revascularisation strategy for proximal coronary lesions it is important to remember that the left main stem is significantly larger in diameter and shorter in length than the LAD, both factors which could impact on long term outcomes with stents. From a scientific perspective this "leap of faith" remains speculative at best because as noted above there are no published trials (first or second generation DES) that shows equivalency of PCI to CABG beyond 12-months of follow-up. Additionally given the lack of contemporary trial data the impact of improved surgical techniques during CABG and increased utilisation of off-pump surgery on the outcomes vs.
PCI is also uncertain.
Revascularisation guidelines
In 2010 In a critical appraisal of the updated 2014 ESC/EACTS guidelines readers might expect that a major change to the proximal LAD revascularisation guidance would be supported by extensive new data since 2010. In fact the upgrade to for PCI from IIa/(B) -that there is conflicting evidence and/or divergence of opinion with the data is derived from a single clinical trial or large non-randomised studies -to IA -that there is general agreement is that the treatment is beneficial, useful and effective with the data the data was derived from multiple clinical trials -is not supported by any referenced data in the guidelines. In fact none of the studies listed in Table 2 2.0) However as discussed above there is a paucity of data which does not appear firm enough to allow definitive conclusions to be drawn and might be interpreted as supporting the continuation of CABG as the preferred treatment.
Thus the data that drive the upgrade of PCI for proximal LAD revascularisation in the guidelines are not clear from the available evidence base.
Summary
In summary although most interventional cardiologists would assert that a 2 nd or 
